fda warning letters compounded semaglutide october 2025 Diabetes advocacy group discourages use of GLP-1 drugs Compounded Semaglutide & Tirzepatide 2025:

This question arises as obesity rates increase among inflammatory bowel disease patients, prompting interest in GLP-1 receptor agonists like semaglutide (Wegovy) and liraglutide (Saxenda)

These findings help explain why females often experience stronger appetite suppression and weight loss on these drugs and suggest that the benefits of GLP-1 analogs could extend to sex-specific treatments for addiction, depression, and even Alzheimers disease

Res Pract

High-dose oral Semaglutide at 50 mg currently appears to be a very good option, showing over 15% weight loss at 68 weeks with relatively low adverse reactions

It strengthens the system that medications like GLP-1 temporarily manipulate